Nuvectis Pharma reports Q2 EPS (30c) vs. (26c) last year

Cash and cash equivalents were $26.8M vs. $18.5M as of December 31, 2024. CEO Ron Bentsur commented, “In Q2 and subsequent weeks we have had a series of important events that we believe put the company in an excellent position for growth. We announced the successful completions of the NXP900 Phase 1a dose escalation study in patients with advanced solid tumors and of the NXP900 drug-drug interaction study in healthy volunteers, both strongly supporting the initiation of the NXP900 Phase 1b program, expected to start imminently. As for NXP800, over the next few months, we plan to explore potential opportunities of NXP800 in cancer types such as endometrial and prostate. On the financial side, in July we strengthened our cash position following the acquisition of shares by a healthcare specialized institutional investor through our ATM facility, bringing our Q2 end proforma cash to approximately $39M, which we expect can fund our operations into 2H 2027. The last few months have been very significant for Nuvectis, and we believe that we are well positioned to deliver on our ambitious plan for NXP900.”